Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846488 | 0.87 | PTGS2 (0.36) | PTGS2PTGS1MAPTALDH1A1SCN9A | |
| SCHEMBL6844095 | 0.84 | MEN1 (0.39) | PTGS2PTGS1LMNANPSR1TSHR | |
| SCHEMBL6846585 | 0.83 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL5377415 | 0.83 | PTGS2 (0.40) | PTGS2PTGS1MAPTSCN9A | |
| SCHEMBL7612387 | 0.83 | PTGS2 (0.39) | PTGS2 | |
| SCHEMBL7617482 | 0.74 | PTGS1 (0.44) | PTGS2PTGS1MAPT | |
| SCHEMBL6742552 | 0.74 | PTGS2 (0.43) | PTGS2PTGS1NR1H2 | |
| SCHEMBL6846588 | 0.73 | PTGS2 (0.39) | PTGS2PTGS1MAPTSCN9A | |
| SCHEMBL6704623 | 0.69 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL10948590 | 0.67 | HSP90AA1 (0.49) | PTGS2ALDH1A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242637-A1 | Tyrosine kinase inhibitors | HARTMAN GEORGE D (US) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242637-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | PTGS2 983/4885PTGS1 791/4885THRB 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.